Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
तुलना करने के लिए मीट्रिक्स | PA8 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPA8पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.6x | −0.6x | |
PEG अनुपात | 0.00 | −0.01 | 0.00 | |
क़ीमत/बुक | 0.0x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 9.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 283.6% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.3% | 7.8% | अनलॉक करें |